Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial.
about
Total pancreatectomy for pancreatic ductal adenocarcinoma: review of the National Cancer Data BaseUtility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancerAnatomical, Physiological, and Molecular Imaging for Pancreatic Cancer: Current Clinical Use and Future ImplicationsNeoadjuvant therapy for pancreas cancer: past lessons and future therapiesNew challenges in perioperative management of pancreatic cancerA Multidisciplinary Approach to Pancreas Cancer in 2016: A Review.Pancreatic cancer: pathobiology, treatment options, and drug delivery.Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database.Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiationAdjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).Adjuvant therapy in pancreatic cancer.Molecular imaging in cancer treatment.Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010.Recent advances and limitations of surgical treatment for pancreatic cancerCurrent status of adjuvant therapy for pancreatic cancer.Neoadjuvant therapy of pancreatic cancer: the emerging paradigm?Is tumour size an underestimated feature in the current TNM system for malignancies of the pancreatic head?A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma.Clinical impact of neoadjuvant treatment in resectable pancreatic cancer: a systematic review and meta-analysis protocol.Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer.Clinically determined type of 18F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer.Neoadjuvant treatment for resectable pancreatic adenocarcinoma.Preoperative predictors for early recurrence of resectable pancreatic cancer.Neoadjuvant therapy for potentially resectable pancreatic cancer: an emerging paradigm?The role of ¹⁸F-FDG PET imaging in upper gastrointestinal malignancies.The role of neoadjuvant therapy in pancreatic cancer: a review.Preoperative imaging evaluation of pancreatic pathologies for the objective prediction of pancreatic fistula after pancreaticoduodenectomy.Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.Prognostic Significance of Muscle Attenuation in Pancreatic Cancer Patients Treated with Neoadjuvant Chemoradiotherapy.Efficacy of Neoadjuvant Versus Adjuvant Therapy for Resectable Pancreatic Adenocarcinoma: A Decision Analysis.Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits.Neoadjuvant therapy for pancreatic cancer: an ongoing debate.Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients.Investigation of Association Between Borderline Pancreatic Head Cancer and Glucose Uptake by Using Positron-Emission Tomographic Studies.Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer.Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: study protocol for an open-label, multicentre, prospective phase II trial (JASPAC05).Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy in patients with resectable T3 pancreatic cancer.Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer.Preoperative chemotherapy does not adversely affect pancreatic structure and short-term outcome after pancreatectomy.
P2860
Q26771577-6F73866C-6AFB-4673-99C0-4CF94DE0211EQ26827392-730863F4-11ED-41D0-AA7D-FBF2C009597CQ26996400-09E0BAA5-73CF-44EF-97B6-47D62B199D9DQ27004292-F97CC2B1-CBBB-491D-A51B-1361E0E1B6FFQ28082422-75AEFDFB-7501-4A4E-8BB6-EDBBA13718B0Q30238706-23ABDE59-7C02-49D3-8166-4A1245D69C79Q33749460-4B13BF5B-C482-4D26-933D-5120452BB55CQ33755147-F3DBDA28-E80D-44B7-9E20-6C13B9B3FA41Q33928176-7CD36938-E581-4530-8DA7-0481A88FF8E9Q33928253-6FF40ACD-F207-4CAC-8975-2842BC96F1A5Q33989437-D9DE3080-3E28-4EF6-B2FD-E9E834316EB5Q34405072-936C8763-4C70-4579-BF67-93EE18811575Q34496670-D28C57CE-998F-467F-A681-AAA7C45473E9Q34635042-946BFDC8-E407-4331-8832-5EB4A7F2B052Q35000847-7ABEA15D-B68E-4928-88B6-F9CEBF54566DQ35583760-FA4A6998-EF8B-47B9-93CE-2FF40983F978Q35776229-D695E24D-7C26-4E61-A120-8E4F49E7E62DQ35854755-5D200D3B-9DA9-472D-ADCB-E4EEC59ADDA0Q35903399-C96E6E4F-37D2-4B5A-805E-82CD1573F5A3Q35970766-D75A27E5-24A1-4CBC-A112-EED6E7646A59Q36023889-2030F0E2-57CD-42F3-B837-A563BC1AF823Q36290046-DF8A783A-D91B-4D9A-A230-DB364A8BCA8CQ36526141-4693DDFB-2B0D-49A2-9776-D4243DBCDD6AQ37576457-7E23FD13-CAE6-40E2-A729-BE190DC0CBB5Q38074622-6E88F4F7-C020-4FC4-8DE5-C2C33CB8B2ACQ38234184-912D6800-E4A3-4D77-B580-88508CD8B3EDQ38734981-9FA179DB-0FA7-4F8C-B57A-E323C597C262Q38831181-17751C78-881E-4A11-BBD4-C28EA19DBA06Q39390859-A2336DFE-5595-471F-96FA-792D56B16D84Q40618487-3154A1FD-9E4A-48AD-9949-4E8C7DAE819AQ40760990-A009A51F-BDFF-4D63-89E6-7D2B7FE2197CQ41573034-798CE62F-E9CF-4511-BFDD-855470CAD47FQ41826893-220D2B10-52FF-4539-8D3E-0218587D9E1BQ42318810-A02D746D-AC20-4A5B-8A2E-F3680E7BF004Q42637699-B7274052-D20E-4E03-84DE-243338D37A24Q42681219-FAFBF5BF-3D89-4E5D-AA26-58FE2C0B7200Q42698514-06461E1F-51D3-4559-A9BD-2F8C51BD2BCAQ44116708-053083B0-9384-4A16-BDBF-2BF285C11D4CQ44650366-94500BD8-0357-4856-88AC-F3D7D004779AQ45846973-22CB032F-9771-4009-8021-0525EF4F49BC
P2860
Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Neoadjuvant chemotherapy gener ...... a prospective phase II trial.
@en
Neoadjuvant chemotherapy gener ...... a prospective phase II trial.
@nl
type
label
Neoadjuvant chemotherapy gener ...... a prospective phase II trial.
@en
Neoadjuvant chemotherapy gener ...... a prospective phase II trial.
@nl
prefLabel
Neoadjuvant chemotherapy gener ...... a prospective phase II trial.
@en
Neoadjuvant chemotherapy gener ...... a prospective phase II trial.
@nl
P2093
P1433
P1476
Neoadjuvant chemotherapy gener ...... a prospective phase II trial.
@en
P2093
Achim Weber
Bernhard C Pestalozzi
Stefan Heinrich
Thomas F Hany
Ujwal Bhure
P304
P356
10.1097/SLA.0B013E318190A6DA
P407
P577
2008-12-01T00:00:00Z